GDF15 and pulmonary hypertension: Finally, the noninvasive, radiological determination of PA/AA-ratio  ≥ 0.80 provides a diagnostic tool that can not only provide valuable information regarding 1-year mortality after TAVR but can also further delineate the risk for pulmonary hypertension with common cardiovascular biomarkers such as cTnI or GDF-15.